This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]
Timeframe: 14 days
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Timeframe: Time on trial up to 60 days